Successful treatment using apatinib in intractable brain edema: A case report and literatures review

References

• Soffietti R, Abacioglu U, Baumert B, Combs SE, Kinhult S, Kros JM, Marosi C, Metellus P, Radbruch A, Villa Freixa SS, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 2017 Apr 10;19(2):162–174. Epub. PubMed PMID: 28391295; PubMed Central PMCID: PMCPMC5620494. doi:10.1093/neuonc/now241.
   PubMed Web of Science ®Google Scholar
• Roth P, Regli L, Tonder M, Weller M. Tumor-associated edema in brain cancer patients: pathogenesis and management. Expert Rev Anticancer Ther. 2013 Oct 25;13(11):1319–1325. Epub. PubMed PMID: 24152171. doi:10.1586/14737140.2013.852473.
   PubMed Web of Science ®Google Scholar
• Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol. 2004 Jul 16;22(14):2865–2872. Epub. PubMed PMID: 15254054. doi:10.1200/jco.2004.12.149.
   PubMed Web of Science ®Google Scholar
• Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002 08 14;94(10):2698–2705. Epub. PubMed PMID: 12173339.
   PubMed Web of Science ®Google Scholar
• Hu WG, Weng YM, Dong Y, Li XP, Song QB. Apatinib in refractory radiation-induced brain edema: A case report. Medicine (Baltimore). 2017 Nov 18;96(46). e7358. Epub. PubMed PMID: 29145238; PubMed Central PMCID: PMCPMC5704783. doi:10.1097/md.0000000000007358.
   PubMed Web of Science ®Google Scholar
• Hladik D, Tapio S. Effects of ionizing radiation on the mammalian brain. Mutat Res. 2016 Dec 07;770(Pt B):219–230. Epub. PubMed PMID: 27919332. doi:10.1016/j.mrrev.2016.08.003
   PubMedGoogle Scholar
• Piazza M, Munasinghe J, Murayi R, Edwards N, Montgomery B, Walbridge S, Merrill M, Chittiboina P. Simulating vasogenic brain edema using chronic VEGF infusion. J Neurosurg. 2017 Jan 07;127(4):905–916. Epub. PubMed PMID: 28059647; PubMed Central PMCID: PMCPMC5542877. doi:10.3171/2016.9.jns1627.
   PubMed Web of Science ®Google Scholar
• Hou J, Kshettry VR, Selman WR, Bambakidis NC. Peritumoral brain edema in intracranial meningiomas: the emergence of vascular endothelial growth factor-directed therapy. Neurosurg Focus. 2013 Dec03;35(6):E2. Epub. PubMed PMID: 24289127. doi:10.3171/2013.8.focus13301.
   PubMed Web of Science ®Google Scholar
• Sabang RL, Gandhiraj D, Fanucchi M, Epelbaum O. Role of bevacizumab in the management of the patient with malignant pleural effusion: more questions than answers. Expert Rev Respir Med. 2018.;12(2):87–94. Epub. [2017 Dec 14]. PubMed PMID: 29235400. doi:10.1080/17476348.2018.1417042.
   PubMed Web of Science ®Google Scholar
• Yang GL, Zhao `Z, Qin TT, Wang D, Chen L, Xiang R, Xi Z, Jiang R, Zhang ZS, Zhang J, et al.. TNFSF15 inhibits VEGF-stimulated vascular hyperpermeability by inducing VEGFR2 dephosphorylation. FASEB J. 2017 Feb 12;31(5):2001–2012. Epub. PubMed PMID: 28183800. doi:10.1096/fj.201600800R.
   PubMed Web of Science ®Google Scholar
• Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007 Jul 31;19(10):2003–2012. Epub. PubMed PMID: 17658244. doi:10.1016/j.cellsig.2007.05.013.
   PubMed Web of Science ®Google Scholar
• Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009 Sep 09;6(10):569–579. Epub. PubMed PMID: 19736552. doi:10.1038/nrclinonc.2009.130.
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999 Aug 07;274(33):23463–23467. Epub. PubMed PMID: 10438525.
   PubMed Web of Science ®Google Scholar
• De Bonis P, Marziali G, Vigo V, Peraio S, Pompucci A, Anile C, Mangiola A. Antiangiogenic therapy for high-grade gliomas: current concepts and limitations. Expert Rev Neurother. 2013 Nov 02;13(11):1263–1270. Epub. PubMed PMID: 24175724. doi:10.1586/14737175.2013.856264.
   PubMed Web of Science ®Google Scholar
• Glitza IC, Guha-Thakurta N, D’Souza NM, Amaria RN, McGovern SL, Rao G, Li J. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. Melanoma Res. 2017 Aug 18;27(6):580–584. Epub. PubMed PMID: 28817446. doi:10.1097/cmr.0000000000000389.
   PubMed Web of Science ®Google Scholar
• Ma Y, Zheng C, Feng Y, Xu Q. Bevacizumab for the Treatment of Gammaknife Radiosurgery-Induced Brain Radiation Necrosis. J Craniofac Surg. 2017 July 28;28(6):e569–e71. Epub. PubMed PMID: 28749838. doi:10.1097/scs.0000000000003874.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al.. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 21;370(8):709–722. Epub. PubMed PMID: 24552318. doi:10.1056/NEJMoa1308345.
   PubMed Web of Science ®Google Scholar
• Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 2010 Oct 07;10:529. Epub. PubMed PMID: 20923544; PubMed Central PMCID: PMCPMC2984425. doi:10.1186/1471-2407-10-529
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19):7099–7109. Epub. PubMed PMID: 15466206. doi:10.1158/0008-5472.can-04-1443.
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–337. Epub 2003/ 01/23.PubMed PMID: 12538485.
   PubMed Web of Science ®Google Scholar
• Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN 3rd, Johnson JH, et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol −6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-b enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem. 2008 Jul 16;51(15):4632–4640. Epub. PubMed PMID: 18620382. doi:10.1021/jm800566m.
   PubMed Web of Science ®Google Scholar